Resolutions passed by Vopak’s Annual General Meeting Resolutions passed by Vopak’s Annual General MeetingRotterdam, the Netherlands, 22 April 2026The Annual General Meeting of Koninklijke Vopak N.V. (Royal Vopak) held on 22 April 2026 passed the following resolutions: Positive advisory vote implementation remuneration policy for the 2025 financial year. Adoption of the financial statements for the 2025 financial year. Approval of the proposed dividend. A dividend of EUR 1.80 per ordinary share with a nominal value of EUR 0.50 will be distributed wholly in cash on 30 April 2026. As f...
1Q adjusted EBITDA decreased by 3% to € 345m which was 6% better than our forecast and 7% above consensus. Akzo still guides for a FY26 adj EBITDA improvement in constant currencies of € 100m . The merger with Axalta is still expected to close in late 2026 or early 2027. Whilst we appreciate the synergies potential from the intended merger, taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 63 TP.
AkzoNobel: 1Q26 beat and FY guidance maintained. ASM International: 1Q26 results, great start to the year. Basic-Fit: Highlights of Capital Markets Day 2026. BE Semiconductor Industries: 1Q26 Preview - building strength. Cofinimmo: Earnings beat, muted investments; Armonea agreement reached. Corbion: Not so sweet. MICC: Peer Danone 1Q26 results. Randstad: Slight beat on 1Q26, trends improving; 2Q26 guidance at least in line. Recticel: 1Q26 in line, sharp pick-up expected in 2Q. ...
Correction: Corbion announces quarterly sales of € 293.7m and Adjusted EBITDA of € 37.8m; maintains full-year outlook Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through the application of science, today publishes its results for Q1 2026 ending 31 March. Key results Q1 2026: • Organic sales growth: -4.1%% ◦ Volume/mix: -2.6% ◦ Price: -1.5% • Sales: € 293.7 million • Adjusted EBITDA: € 37.8 million • Operating profit: € 14.7 million Outlook FY 2026: FY 2026 outlook affirmed € millionQ1 2026Q1 2025 Total growthOrganic growthSales293.7...
Vopak reported better than expected 1Q26 numbers with proportional EBITDA of €295m vs. our €276m and consensus of €286m. So far the company foresees no material financial impact at group level stemming from the Iran conflict. The proportional EBITDA and free operating CF outlook for 2026 were maintained. Occupancy rates held up well at 91% vs. 92% last quarter. 1Q26 update confirms our appraisal of Vopak as an attractively priced, defensive grower. We reiterate our Buy rating and €56 TP.
1Q26 revenue increased by 6.1%, which was in line with our and consensus forecasts and driven by recent acquisitions. Recticel mentions a clear acceleration in volumes and order books, although this seems partly driven by customers that are pre-buying in the light of significant price increases on the back of the situation in the Middle East. Recticel does not provide a FY guidance at this stage. We believe Recticel still has significant firepower for additional acquisitions and we would expect ...
1Q26 adj EBITDA decreased by 20% organically, impacted by a higher comparable base and phasing (as previously guided for). Despite the softer than expected 1Q, FY26 guidance of a c. 100bps adj EBITDA margin improvement to around 17% is maintained (KBCS 16.8%, CSS 16.7%). The divestment process for the PLA JV stake is still ongoing. We remind that the late 2025 strategy update revealed also that Biochemicals will be de-emphasized, which will put the growth focus on food preservation and formulati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.